BioMérieux: Invest Securities reiterates its opinion
(CercleFinance.com) - While lowering its target price from ?127 to ?120, Invest Securities reiterates its 'buy' opinion on bioMérieux, 'an unfairly discounted stock in the IVD (in vitro diagnostics) industry, given its remarkable ability to navigate the post-Covid environment'.
The 2024 P/E for the next financial year is around 23 times, with a yield close to 1%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.